Skip to content
Screener

Travere Therapeutics, Inc. TVTX Q2 2025 earnings

Reported August 6, 2025 · After market close

Revenue$114.4MBeat by $14.9M
EPS-$0.14Beat by $0.14
Revenue estimate$99.5M
EPS estimate-$0.28

Next report

Oct 29, 2026 (in a month)
Revenue estimate$195.7M
EPS estimate$0.05

Financials

Q2 2025

Income statement

See full
Revenue$114.4M+111%
Gross profit$112.9M+117%
Operating income-$12.7M+81.3%
Net income-$12.8M+81.9%
EPS (diluted)-$0.14+84.6%

Balance sheet

See full
Cash & equivalents$75.2M+133%
Total debt$88.6M+253%
Total equity$32.7M+116%
Total assets$555.3M+0.8%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$1.35B+113%
Enterprise value$1.37B+118%
P/S4.1×+0.5×

Profitability

See full
Gross margin96.9%+2.2pp
Operating margin-51.6%-22.4pp
Net margin-50.6%-14.0pp

Returns & leverage

See full
Return on equity-706%-1,302pp
Debt / equity2.7×+1.0×
Current ratio2×-1.0×

Segments

By segment

See full
Reportable Segment$114.4M+111%

By product

See full
License and collaboration revenue$19.6M—

FAQ

When did Travere Therapeutics, Inc. report Q2 2025 earnings?
Travere Therapeutics, Inc. (TVTX) reported Q2 2025 earnings on August 6, 2025 after market close.
What were Travere Therapeutics, Inc.'s Q2 2025 revenue and EPS?
Travere Therapeutics, Inc. reported revenue of $114.4M and eps of $-0.14 for Q2 2025.
Did Travere Therapeutics, Inc. beat estimates in Q2 2025?
Revenue beat the consensus estimate of $99.5M by $14.9M. EPS beat the consensus estimate of $-0.28 by $0.14.
How did Travere Therapeutics, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 111.5% from $54.1M a year earlier and eps grew 84.4% from $-0.90.
Where can I find Travere Therapeutics, Inc.'s Q2 2025 SEC filings?
You can read the 8-K earnings release (0001438533-25-000045) and the 10-Q periodic report (0001438533-25-000046) directly on SEC EDGAR. The filing index links above go to sec.gov.